PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11009478-1	2000	Milrinone, a phosphodiesterase 3 (PDE3) inhibitor, is known to enhance left ventricular (LV) contractility by an inhibition of the breakdown of cAMP through the mechanism inhibiting PDE3.	Milrinone	0-9	cathelicidin antimicrobial peptide	Homo sapiens	144-148	
11009478-6	2000	In LV crude homogenate, the thapsigargin-sensitive, Ca(2+)-ATPase activity-cAMP relationships was significantly less increased by milrinone compared with dobutamine (P < 0.05), indicating the higher sensitivity of the SR Ca(2+)-ATPase activity on cAMP by milrinone than by dobutamine.	Milrinone	130-139	cathelicidin antimicrobial peptide	Homo sapiens	75-79	
11009478-6	2000	In LV crude homogenate, the thapsigargin-sensitive, Ca(2+)-ATPase activity-cAMP relationships was significantly less increased by milrinone compared with dobutamine (P < 0.05), indicating the higher sensitivity of the SR Ca(2+)-ATPase activity on cAMP by milrinone than by dobutamine.	Milrinone	130-139	cathelicidin antimicrobial peptide	Homo sapiens	250-254	
11009478-6	2000	In LV crude homogenate, the thapsigargin-sensitive, Ca(2+)-ATPase activity-cAMP relationships was significantly less increased by milrinone compared with dobutamine (P < 0.05), indicating the higher sensitivity of the SR Ca(2+)-ATPase activity on cAMP by milrinone than by dobutamine.	Milrinone	258-267	cathelicidin antimicrobial peptide	Homo sapiens	75-79	
9776319-4	1998	Milrinone and cilostamide inhibited migration induced by an optimal concentration of cAMP.	Milrinone	0-9	cathelicidin antimicrobial peptide	Homo sapiens	85-89	
7995950-5	1995	FMLP-mediated adhesion was inhibited by a diverse group of cAMP modulators: forskolin, isoproterenol, phosphodiesterase IV inhibitors (rolipram and Ro 20-1724), but not phosphodiesterase III inhibitors (milrinone and bemoradan).	Milrinone	203-212	cathelicidin antimicrobial peptide	Homo sapiens	59-63	
8097971-4	1993	In contrast, there is serious concern that agents that act predominantly through PDE inhibition and thereby increase cellular cyclic AMP (cAMP) content, e.g., amrinone, milrinone, and enoximone, not only are ineffective in heart failure but also may lead to serious adverse events, i.e., arrhythmogenicity, and may increase mortality rate in advanced heart failure.	Milrinone	169-178	cathelicidin antimicrobial peptide	Homo sapiens	126-143